Jee Hamlyn-Harris | IR |
Adam Elsesser | Chairman and CEO |
Maggie Yuen | CFO |
Sri Kosaraju | President |
Jason Mills | Canaccord Genuity |
Robbie Marcus | JPMorgan |
Bob Hopkins | Bank of America |
Larry Biegelsen | Wells Fargo |
[Starts Abruptly] Fourth Quarter and Year-End 2019. A copy of the press release and financial tables, which includes the GAAP to non-GAAP reconciliations can be viewed under the Investors tab on our company website at www.penumbrainc.com.
During the course of this conference call, the company will make forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial performance, commercialization, clinical trials, regulatory status, quality, compliance and business trends. Actual results could differ materially from those stated or implied by our forward-looking statements due to certain risks and uncertainties, including those described in our 10-K for the year-ended December 31, 2019 which is scheduled to be filed with the SEC on February 25, 2020.
As a result, we caution you against placing undue reliance on these forward-looking statements, and we encourage you to review our periodic filings with the SEC, including the 10-K previously mentioned for a more complete discussion of these factors and other risks that may affect our future results or the market price of our stock.